BALTIMORE, May 26, 2021 /PRNewswire/ -- Prosit Sole Biotechnology, a clinical-stage biotech company developing novel protein therapeutics, today announces that it has initiated the first-in-human ("FIH") Phase I clinical trial of PSP001 in US. PSP001 is a novel, long acting and potent interferon lambda chimera injection. The first dose was
Type III interferons (IFN's), also termed interferon lambda's (IFNλ's) constitute a new addition to the IFN family. Their unique receptor IFNλR1 is particularly abundant at the barrier surfaces, such as the respiratory tracts, the gastrointestinal tracts, and the liver. Non-redundant to type I interferons (IFNα and IFNβ), IFNλ's exhibit unique antiviral and immune modulatory activities. Prosit Sole Biotechnology is developing PSP001 for the treatment of chronic norovirus enteritis in hematopoietic and solid organ transplant recipients.
"Chronic norovirus enteritis in immunocompromised patients is an urgent unmet medical need. There are no approved therapies for this debilitating disease." said Hongyu Liu, PhD, CEO of Prosit Sole Biotechnology. "We are also actively developing PSP001 for additional indications such as chronic hepatitis B."
Investor Contact:
Email: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
Media Contact:
Cindy YuEmail: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
Source: Prosit Sole Biotechnology
To learn more, please visit http://www.prositsole.com/
